Eli Lilly and Company (LLY) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Eli Lilly and Company stock (LLY) is currently trading at $916.31. Eli Lilly and Company PE ratio is 39.68. Eli Lilly and Company PS ratio (Price-to-Sales) is 12.40. Analyst consensus price target for LLY is $1209.34. WallStSmart rates LLY as Buy.
Eli Lilly and Company (LLY) stock price prediction for 2030: Base case $886.92. Bull case $1108.65. Bear case $665.19. See full LLY 2030 price forecast and methodology on WallStSmart.
- LLY PE ratio analysis and historical PE chart
- LLY PS ratio (Price-to-Sales) history and trend
- LLY intrinsic value — DCF, Graham Number, EPV models
- LLY stock price prediction 2025 2026 2027 2028 2029 2030
- LLY fair value vs current price
- LLY insider transactions and insider buying
- Is LLY undervalued or overvalued?
- Eli Lilly and Company financial analysis — revenue, earnings, cash flow
- LLY Piotroski F-Score and Altman Z-Score
- LLY analyst price target and Smart Rating
Eli Lilly and Company
📊 No data available
Try selecting a different time range
LLY Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Eli Lilly and Company (LLY)
LLY is trading near its Graham intrinsic value of $1065.17, suggesting the stock is reasonably priced at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Eli Lilly and Company (LLY) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, return on equity. Concerns around price/sales and price/book. Overall metrics suggest strong investment potential with favorable risk/reward.
Eli Lilly and Company (LLY) Key Strengths (8)
Mega-cap company, among the largest in the world
Growing significantly faster than its price suggests
Every $100 of shareholder equity generates $101 in profit
Keeps $45 of every $100 in revenue after operating costs
Revenue surging 42.60% year-over-year
Earnings per share surging 51.40% year-over-year
Keeps $32 of every $100 in revenue as net profit
84.75% of shares held by major funds and institutions
Supporting Valuation Data
Eli Lilly and Company (LLY) Areas to Watch (2)
Very expensive at 12.4x annual revenue
Very expensive at 30.4x book value
Supporting Valuation Data
Eli Lilly and Company (LLY) Detailed Analysis Report
Overall Assessment
This company scores 80/100 in our Smart Analysis, earning a A- grade. Out of 10 metrics analyzed, 8 register as strengths (avg 10.0/10) while 2 fall into concern territory (avg 2.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Market Cap, PEG Ratio, Return on Equity. Valuation metrics including PEG Ratio (0.97) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 101.20%, Operating Margin at 44.90%, Profit Margin at 31.70%. Growth metrics are encouraging with Revenue Growth at 42.60%, EPS Growth at 51.40%.
The Bear Case
The primary concerns are Price/Sales, Price/Book. Some valuation metrics including Price/Sales (12.40), Price/Book (30.39) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 101.20% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 42.60% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of Market Cap and PEG Ratio makes a compelling case at current levels. The key risk is Price/Sales, but the overall fundamental picture is positive with a clear path to maintaining or improving the current A- grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
LLY Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
LLY's Price-to-Sales ratio of 12.40x trades 256% above its historical average of 3.48x (96th percentile), historically expensive. The current valuation is 9% below its historical high of 13.6x set in Mar 2026, and 685% above its historical low of 1.58x in Feb 2009.
WallStSmart Analysis Synopsis
Data-driven financial summary for Eli Lilly and Company (LLY) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
Eli Lilly and Company is a strong growth company balancing expansion with improving profitability. Revenue reached 65.2B with 43% growth year-over-year. Profit margins are strong at 31.7%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 43% YoY, reaching 65.2B. This pace significantly outperforms most DRUG MANUFACTURERS - GENERAL peers.
ROE of 10120.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Eli Lilly and Company maintain 43%+ revenue growth, or will competition slow it down?
Debt management: total debt of 42.5B is significantly higher than cash (7.2B). Monitor refinancing risk.
Sector dynamics: monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive moves, and regulatory changes that could impact Eli Lilly and Company.
Bottom Line
Eli Lilly and Company offers an attractive blend of growth (43% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Eli Lilly and Company(LLY)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.